Chimeric, Mutated, Or Recombined Hybrid (e.g., Bifunctional, Bispecific, Rodent-human Chimeric, Single Chain, Rfv, Immunoglobulin Fusion Protein, Etc.) Patents (Class 530/387.3)
  • Patent number: 11357866
    Abstract: A composition of matter and method of treating HIV with mesenchymal stem cells (MSC) is disclosed. Specifically, MSCs are transduced with vectors incorporating an anti-viral fusion inhibitor, such as a C46-derived peptide or neutralizing antibody. The transduced MSCs are capable of expression the inhibitor and preventing HIV virus-cell fusion.
    Type: Grant
    Filed: June 7, 2018
    Date of Patent: June 14, 2022
    Assignee: THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
    Inventors: Stephen E. Braun, Debasis Mondal, Bruce A Bunnell, Narae Lee
  • Patent number: 11351269
    Abstract: Disclosed are antibodies, including antibody drug conjugates, that specifically bind to NTB-A. Also disclosed are methods for using the anti-NTB-A antibodies to detect or modulate activity of (e.g., inhibit proliferation of) an NTB-A-expressing cell, as well as for diagnoses or treatment of diseases or disorders (e.g., cancer) associated with NTB-A-expressing cells, such as multiple myeloma, non-Hodgkin lymphoma and acute myeloid leukemia.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: June 7, 2022
    Assignee: Seagen Inc.
    Inventors: Timothy Lewis, Lori Westendorf, Django Sussman, Che-Leung Law
  • Patent number: 11325981
    Abstract: Provided herein are biparatopic antigen-binding constructs that specifically bind HER2. The biparatopic antigen-binding constructs comprise one antigen-binding moiety that binds to ECD2 of HER2, a second antigen-binding moiety that binds to ECD4 of HER2, and an Fc. At least one of the antigen-binding moieties is an scFv. The biparatopic antigen-binding constructs can be used in the treatment of cancer.
    Type: Grant
    Filed: June 18, 2018
    Date of Patent: May 10, 2022
    Assignee: Zymeworks Inc.
    Inventors: Nina E. Weisser, Gordon Yiu Kon Ng, Grant Raymond Wickman, Surjit Bhimarao Dixit, Eric Escobar-Cabrera, Mario Sanches
  • Patent number: 11326182
    Abstract: The invention provides compositions and methods for the preparation, manufacture and therapeutic use of viral vectors, such as adeno-associated virus (AAV) particles having viral genomes encoding one or more antibodies or antibody fragments or antibody like polypeptides, for the prevention and/or treatment of diseases and/or disorders.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: May 10, 2022
    Assignee: Voyager Therapeutics, Inc.
    Inventors: Steven Paul, Donna T. Ward
  • Patent number: 11319365
    Abstract: The present disclosure relates to antibodies that bind selectively to pathological Tau, including compositions and methods relating to such antibodies, such as for treating tauopathies, neurodegenerative diseases associated with pathological aggregation of Tau.
    Type: Grant
    Filed: September 10, 2021
    Date of Patent: May 3, 2022
    Assignee: APRINOIA THERAPEUTICS LIMITED
    Inventors: Ming-Kuei Jang, Chin-Yin Tai
  • Patent number: 11319526
    Abstract: The invention provides methods and compositions for preparing antibodies and antibody derivatives with reduced core fucosylation.
    Type: Grant
    Filed: May 16, 2019
    Date of Patent: May 3, 2022
    Assignee: Seagen Inc.
    Inventors: Stephen C. Alley, Scott C. Jeffrey, Django Sussman, Dennis R. Benjamin, Brian Toki, Patrick J. Burke
  • Patent number: 11319379
    Abstract: Disclosed are compositions and methods for targeted treatment of TAG-72-expressing cancers. In particular, affinity maturated single chain variable fragment (scFv) antibodies that bind TAG-72 on cancer cells are disclosed.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: May 3, 2022
    Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Inventor: Hatem Soliman
  • Patent number: 11312779
    Abstract: The present invention relates to methods of treating patients suffering from Contact dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia aereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination by administering an IL-31RA antagonist.
    Type: Grant
    Filed: February 28, 2020
    Date of Patent: April 26, 2022
    Assignee: ZYMOGENETICS, INC.
    Inventor: Janine M. Bilsborough
  • Patent number: 11267870
    Abstract: Modified Fc regions of antibodies and antibody fragments, both human and humanized, and having enhanced stability and efficacy, are provided. Fc regions with core fucose residues removed, and attached to oligosaccharides comprising terminal sialyl residues, are provided. Antibodies comprising homogeneous glycosylation of Fc regions with specific oligosaccharides are provided. Fc regions conjugated with homogeneous glycoforms of monosaccharides and trisaccharides, are provided. Methods of preparing human antibodies with modified Fc using glycan engineering, are provided.
    Type: Grant
    Filed: October 2, 2018
    Date of Patent: March 8, 2022
    Assignee: ACADEMIA SINICA
    Inventors: Chi-Huey Wong, Chung-Yi Wu
  • Patent number: 11261262
    Abstract: The invention provides heterodimer bispecific antigen-binding molecules that include a first polypeptide that does not include an IgG CH1 domain and a second polypeptide where there is at least one mutation in the IgG CH3 domain that abolishes the ability of the second polypeptide to bind CH3-specific affinity media such that the first and second polypeptides have different affinities with respect to CH1 and CH3 specific affinity reagents that allows rapid isolation by differential binding. The invention also provides bispecific antibodies that have CH1 and CH3 regions with different affinities with respect to affinity reagents that allows rapid isolation by differential binding. The invention also concerns bispecific antibodies which are heterodimers of two IgG heavy chains that differ by at least two amino acids that allow for rapid isolation based on a differential affinity of one mutated heavy chain and a second mutated heavy chain toward two different affinity reagents.
    Type: Grant
    Filed: September 3, 2014
    Date of Patent: March 1, 2022
    Assignee: NovImmune SA
    Inventors: Nicolas Fischer, Giovanni Magistrelli, Francois Rousseau, Krzysztof Masternak, Pauline Malinge
  • Patent number: 11261238
    Abstract: The current invention reports a method for purifying an immunoglobulin, wherein the method comprises applying an aqueous, buffered solution comprising an immunoglobulin in monomeric and in aggregated form to a cation exchange material under conditions whereby the immunoglobulin in monomeric form does not bind to the cation exchange material, and recovering the immunoglobulin in monomeric form from the solution after the contact with the cation exchange material.
    Type: Grant
    Filed: February 3, 2020
    Date of Patent: March 1, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Roberto Falkenstein, Claudia Giessel
  • Patent number: 11235059
    Abstract: The present invention provides antibodies that bind FGFR2IIIb, wherein the antibodies are afucosylated. The present invention provides compositions comprising antibodies that bind FGFR2IIIb, wherein at least 95% of the antibodies in the composition are afucosylated. In some embodiments, methods of treating cancer comprising administering afucosylated anti-FGFR2IIIb antibodies are provided.
    Type: Grant
    Filed: November 6, 2018
    Date of Patent: February 1, 2022
    Assignee: Five Prime Therapeutics, Inc.
    Inventors: Thomas Harding, Kristen Pierce, Namrata Patil, Thomas Brennan, Julie Hambleton
  • Patent number: 11225528
    Abstract: The present invention is directed to novel heterodimeric antibodies.
    Type: Grant
    Filed: March 14, 2019
    Date of Patent: January 18, 2022
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal, Sung-Hyung Lee
  • Patent number: 11214627
    Abstract: The present invention relates to the area of improved anti-IgE antibodies and antigen binding agents, and compositions thereof, which target IgE, for instance: for use in treating disorders caused by IgE (such as allergic responses, or certain autoimmune responses); and, in particular, disorders caused by the interaction of IgE with the Fc?RI receptor. In particular, this invention relates to improved anti-IgE antibodies and antigen binding agents related to novel mutants of omalizumab (Xolair®). The improved anti-IgE antibodies and antigen binding agents of the invention may have improved affinity for IgE and/or an improved interaction with the C?2 domain of IgE and/or an improved modified epitope on IgE (for instance further involving the C?2 domain of IgE) and/or the ability to disassociate IgE from the Fc?RI receptor for instance at pharmaceutically-relevant concentrations.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: January 4, 2022
    Assignee: UCB BIOPHARMA SRL
    Inventors: Ralph Adams, Thomas Allen Ceska, Anna Marie Davies, Alistair James Henry, Xiaofeng Liu, James Michael McDonnell, Brian John Sutton, Marta Katarzyna Westwood
  • Patent number: 11214791
    Abstract: A binding agent to a target molecule, or method or kit where the binding agent is selected from a library where each variant has a circular permutation of the FHA domain where the rearrange does not substantially disrupt the FHA domain's beta-sheet scaffold or increase the stability of the beta-sheet scaffold. The randomized regions of the FHA domain include the endogenous binding interface the FHA domain, the region opposite of the endogenous binding interface, and the circular permutation region.
    Type: Grant
    Filed: April 25, 2017
    Date of Patent: January 4, 2022
    Inventors: Rajika Perera, Michael Longo
  • Patent number: 11203643
    Abstract: Disclosed herein are humanized anti-CD137 antibodies and methods of using such for eliciting CD137 signaling, thereby enhancing immune responses such as T cell functions. The antibodies disclosed within may be used to treat diseases, such as cancer and immune disorders.
    Type: Grant
    Filed: March 19, 2021
    Date of Patent: December 21, 2021
    Assignee: LYVGEN BIOPHARMA HOLDINGS LIMITED
    Inventors: Jieyi Wang, Yi Wu
  • Patent number: 11192953
    Abstract: The invention provides antibodies that specifically bind to OX40 (CD134), referred to as OX40 antibodies, anti-OX40 or anti-OX40 antibodies. Invention antibodies that specifically bind to OX40 include mammalian (human, primate, etc.), humanized and chimeric anti-OX40 antibodies. Invention antibodies and antibody subsequences (fragments) that specifically bind to OX40 include purified and isolated antibodies, as well as pharmaceutical formulations thereof, are useful in various methods including treatment, screening and detection methods.
    Type: Grant
    Filed: May 14, 2018
    Date of Patent: December 7, 2021
    Assignee: KYOWA KIRIN CO., LTD.
    Inventors: Shinichiro Kato, Rachel Soloff Nugent, Hitoshi Yoshida, Michael Croft
  • Patent number: 11186642
    Abstract: In one embodiment, a masked monoclonal antibody (mAb) is provided, the mAb, encoded by a nucleic acid sequence or an amino acid sequence molecule comprising a signal sequence, a masking epitope sequence, a linker sequence that is cleavable by a protease specific to a target tissue; and an antibody or a functional fragment thereof. In another embodiment, a cross-masked mAb heterodimer complex is provided, comprising a first masked mAb, comprising a first signal sequence, a first masking epitope sequence, a first linker that is cleavable by a protease specific to a target tissue, and a first antibody or fragment thereof; and a second masked mAb, comprising a second signal sequence, a second masking epitope sequence, a second linker that is cleavable by a protease specific to a target tissue, and a second antibody or fragment thereof.
    Type: Grant
    Filed: February 22, 2017
    Date of Patent: November 30, 2021
    Assignees: CITY OF HOPE, THOMAS JEFFERSON UNIVERSITY
    Inventors: John C. Williams, Ulrich Rodeck, Joshua M. Donaldson, Csaba Kari
  • Patent number: 11168149
    Abstract: The disclosure is directed to a heterodimer molecule, comprising a first polypeptide chain and a second polypeptide chain, and the first polypeptide chain comprises a first CH3 domain of an antibody heavy chain constant region, the second polypeptide chain comprises a second CH3 domain of an antibody heavy chain constant region. Comparing to a corresponding wild-type CH3 domain of a human antibody heavy chain constant region, the first CH3 domain and the second CH3 domain comprise amino acid mutations at specific positions, for example T366+K409+K392 and T366+L368+Y407+D399+F405, respectively.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: November 9, 2021
    Assignees: JIANGSU ALPHAMAB BIOPHARMACEUTICALS CO., LTD., SUZHOU ALPHAMAB CO., LTD.
    Inventor: Ting Xu
  • Patent number: 11168112
    Abstract: Fusion proteins of C1q peptides and HMBG1 A-box or HMBG1 B-box, or C1q peptides and DWESY peptide are provided, and methods of use thereof.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: November 9, 2021
    Assignee: THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH
    Inventor: Betty A. Diamond
  • Patent number: 11135262
    Abstract: This invention relates to the treatment of cervical tumor caused by human papillomavirus (HPV) infection. In particular, the invention provides methods for improving cervical tumor treatment and methods for treating cervical tumor caused by HPV infection using a polynucleotide encoding an E6/E7 fusion protein.
    Type: Grant
    Filed: August 14, 2015
    Date of Patent: October 5, 2021
    Assignee: GENEXINE, INC.
    Inventors: Hyun-Tak Jin, Hye Seong Lim, You Suk Suh, Eun Joo Nam
  • Patent number: 11111315
    Abstract: The present invention is directed to novel heterodimeric antibodies.
    Type: Grant
    Filed: April 4, 2018
    Date of Patent: September 7, 2021
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal, Sung-Hyung Lee
  • Patent number: 11098105
    Abstract: Provided herein are heteromultimer constructs with reduced or silenced effector function. In an embodiment is provided a heteromultimer construct comprising an IgG Fc construct having a first and a second Fc polypeptide, each Fc polypeptide comprising a modified lower hinge region wherein: the modified lower hinge region of said first Fc polypeptide comprises at least one amino acid modification, the modified lower hinge region of said second Fc polypeptide comprises at least one amino acid modification which is different from at least one amino acid modification of said first Fc polypeptide, and the IgG Fc construct displays reduced binding to all Fc? receptors and to C1q protein as compared to a corresponding parent IgG Fc construct. Also provided are methods of producing such heteromultimer constructs, and methods of reducing ADCC for an antibody construct by reducing effector function.
    Type: Grant
    Filed: May 30, 2014
    Date of Patent: August 24, 2021
    Assignee: ZYMEWORKS INC.
    Inventor: Eric Escobar-Cabrera
  • Patent number: 11065341
    Abstract: The present invention generally provides compositions methods and composition relating to the diagnosis and/or treatment of cancers having a cell surface de-N-acetylated sialic acid antigen, e.g., an at least partially de-N-acetylated ganglioside and/or a de-N-acetylated sialic acid-modified cell surface protein.
    Type: Grant
    Filed: December 12, 2017
    Date of Patent: July 20, 2021
    Assignee: Children's Hospital & Research Center at Oakland
    Inventors: Gregory R. Moe, Charles Paul Plested
  • Patent number: 11065286
    Abstract: Provided herein are oncolytic vaccinia viruses which have been modified to contain an exogenous nucleic acid that codes for a variant HMGB1 protein. Such vaccinia viruses modified to contain nucleic acid encoding variant HMGB1 and that express a variant HMGB1 or a fragment thereof can achieve a synergistic effect in combination with chemotherapy. Methods of using oncolytic vaccinia viruses modified to contain an exogenous nucleic acid that codes for a variant HMGB1 protein, in the treatment of various cancers, are also provided.
    Type: Grant
    Filed: September 21, 2017
    Date of Patent: July 20, 2021
    Inventor: Stephen H. Thorne
  • Patent number: 11053317
    Abstract: Disclosed is a pharmaceutical preparation comprising a CD147 monoclonal antibody, a buffer, a protein protectant and a surfactant. The pharmaceutical preparation can maintain the stability of the CD147 monoclonal antibody over a long period of time. Also disclosed are the use of the pharmaceutical preparation in the preparation of a drug for treating CD147-related diseases, in particular non-small cell lung cancer, and a method for preparing the pharmaceutical preparation.
    Type: Grant
    Filed: December 27, 2017
    Date of Patent: July 6, 2021
    Assignee: JIANGSU PACIFIC MEINUOKE BIO-PHARMACEUTICAL CO., LTD.
    Inventors: Hao Tang, Qiang Feng, Xiaochun Chen
  • Patent number: 11053314
    Abstract: Described herein is the discovery that cancer stem cells (CSCs) can be induced to differentiate by altering CD47 signaling. Provided herein are methods and compositions for inducing differentiation of cancer stem cells, for instance irreversible differentiation, including methods of treating subjects with cancer such as breast cancer, colon cancer, lung cancer, ovarian cancer, or melanoma, and including metastatic as well as primary cancer. Also provided are methods for treating subjects with triple negative breast cancers involving forcing differentiation of bCSCs of the subjects through targeting of CD47.
    Type: Grant
    Filed: October 9, 2015
    Date of Patent: July 6, 2021
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: David D. Roberts, Sukhbir Kaur, Chengyu Liu
  • Patent number: 11053303
    Abstract: The present invention relates to a labeled chimeric non-therapeutic antibodylike protein comprising, in a hypervariable region thereof, an enzyme cleavable peptide sequence derived from a hypervariable region of a reference therapeutic antibody.
    Type: Grant
    Filed: September 17, 2018
    Date of Patent: July 6, 2021
    Assignee: PROMISE PROTEOMICS
    Inventors: Dorothée Lebert, Guillaume Picard
  • Patent number: 11045530
    Abstract: The invention is directed to T cell epitopes wherein said epitopes comprises a peptide or polypeptide chain comprising at least a portion of an immunoglobulin constant or variable region. The invention also relates to methods of using and methods of making the epitopes of the invention.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: June 29, 2021
    Assignee: EpiVax, Inc.
    Inventors: Anne De Groot, William Martin, Daniel S. Rivera
  • Patent number: 11045528
    Abstract: The invention is directed to T cell epitopes wherein said epitopes comprises a peptide or polypeptide chain comprising at least a portion of an immunoglobulin constant or variable region. The invention also relates to methods of using and methods of making the epitopes of the invention.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: June 29, 2021
    Assignee: EpiVax, Inc.
    Inventors: Anne De Groot, William Martin, Daniel S. Rivera
  • Patent number: 11040120
    Abstract: The present invention relates to a kit for radiolabelling a targeting agent with gallium-68. The present invention also relates to the use of the kit for radiolabelling a targeting agent, a method for radiolabelling a targeting agent with gallium-68 using the kit, and a method of preparation of the kit.
    Type: Grant
    Filed: July 28, 2015
    Date of Patent: June 22, 2021
    Assignee: ANMl S.A.
    Inventors: Ludovic Wouters, Geoffroy Kaisin, André Luxen, Marc Léonard, Samuel Voccia
  • Patent number: 11034765
    Abstract: This invention relates to anti-PD-1 antibodies and methods of using them in treating diseases and conditions related to PD-1 activity, e.g., cancer.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: June 15, 2021
    Assignee: Symphogen A/S
    Inventors: Gunther Galler, Monika Gad, Klaus Koefoed, Ivan D. Horak, Thomas Bouquin, Michael Kragh, Mikkel Pedersen
  • Patent number: 11027030
    Abstract: The present invention relates to a kit for radiolabelling a targeting agent with gallium-68. The present invention also relates to the use of the kit for radiolabelling a targeting agent, and a method for radiolabelling a targeting agent with gallium-68 using the kit.
    Type: Grant
    Filed: May 17, 2018
    Date of Patent: June 8, 2021
    Assignee: ANMI S.A.
    Inventors: Ludovic Wouters, Geoffroy Kaisin, André Luxen, Marc Léonard, Samuel Voccia
  • Patent number: 11027016
    Abstract: Disclosed is a pharmaceutical preparation comprising a CD147 monoclonal antibody, a buffer, a protein protectant and a surfactant. The pharmaceutical preparation can maintain the stability of the CD147 monoclonal antibody over a long period of time. Also disclosed are the use of the pharmaceutical preparation in the preparation of a drug for treating CD147-related diseases, in particular non-small cell lung cancer, and a method for preparing the pharmaceutical preparation.
    Type: Grant
    Filed: December 27, 2017
    Date of Patent: June 8, 2021
    Inventor: Xiaochun Chen
  • Patent number: 11021544
    Abstract: The present invention relates to dimers comprising a first polypeptide and a second polypeptide, wherein each of said first and second polypeptide comprises at least one immunoglobulin single variable domain (ISVD) and a C-terminal extension comprising a cysteine moiety (preferably at the C-terminus), wherein said first polypeptide and said second polypeptide are covalently linked via a disulfide bond between the cysteine moiety of said first polypeptide and the cysteine moiety of said second polypeptide, in which the dimer outperformed the benchmark constructs, e.g. cognate multivalent and multispecific constructs, in various assays. The present invention provides methods for making the dimers of the invention.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: June 1, 2021
    Assignee: Ablynx N.V.
    Inventors: Carlo Boutton, Daniel Janssen, Peter Casteels, Peter Schotte, Francis Descamps
  • Patent number: 11021530
    Abstract: The present invention relates to the field of biotechnology, and in particular to the field of antibodies. Provided herein are novel methods for removing glycosylated antibody variants from an antibody preparation, an antibody preparation obtained by said method, and a pharmaceutical composition comprising the same.
    Type: Grant
    Filed: October 30, 2017
    Date of Patent: June 1, 2021
    Assignee: Hexal AG
    Inventors: Claudia Torella, Benjamin Hackner, Carsten Funke, Michael Otten, Christina Hildebrandt, Renate Lafuntal, Florian Wolschin
  • Patent number: 11001611
    Abstract: The present disclosure relates to relates methods and associated compositions that provide fast, efficient site-selective conjugation of a protein, such as the pore-forming protein ?-hemolysin, to a biomolecule, such as a DNA polymerase, and the use of such site-selective protein-biomolecule conjugates in nanopore devices and methods.
    Type: Grant
    Filed: September 18, 2018
    Date of Patent: May 11, 2021
    Assignee: Roche Sequencing Solutions, Inc.
    Inventors: Dmitriy Gremyachinskiy, Christos Tzitzilonis
  • Patent number: 10988537
    Abstract: Antibodies, antigen-binding proteins and Fc-fusion proteins that comprise recombinant polypeptides containing a chimeric heavy chain constant region sequence are provided that bind to certain Fc receptors however have reduced effector functions. Methods of making constructs for expression of such chimeric Fc-containing antibodies, antigen-binding proteins and Fc-fusion proteins in cell systems, and methods of producing and isolating the chimeric Fc-containing proteins are provided.
    Type: Grant
    Filed: September 12, 2018
    Date of Patent: April 27, 2021
    Assignee: Regeneren Pharmaceuticals, Inc.
    Inventors: Samuel Davis, Eric Smith, Supriya Patel
  • Patent number: 10982221
    Abstract: The present invention describes the plant-based production of a therapeutic anti-virus antibody.
    Type: Grant
    Filed: January 27, 2015
    Date of Patent: April 20, 2021
    Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
    Inventors: Qiang Chen, Huafang Lai, Jonathan Hurtado
  • Patent number: 10982008
    Abstract: The invention provides for a domain-exchanged antibody comprising a light chain (LC) composed of VL-CH3, and a heavy chain (HC) comprising VH-CH3-CH2-CH3, wherein the VL-CH3 of the LC is dimerising with the VH-CH3 of the HC thereby forming a domain-exchanged LC/HC dimer comprising a CH3LC/CH3HC domain pair, and means and method for producing the same.
    Type: Grant
    Filed: December 4, 2015
    Date of Patent: April 20, 2021
    Assignee: MERCK PATENT GMBH
    Inventors: Gordana Wozniak-Knopp, Sylvia Dietrich, Florian Rüker, Alec Gross, Stefan Becker
  • Patent number: 10973904
    Abstract: The present invention relates to immunogenic immune complexes, related compositions, and related methods.
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: April 13, 2021
    Assignee: The Rockefeller University
    Inventors: Jeffrey V. Ravetch, Taia Wang, Jad Mamaary
  • Patent number: 10947268
    Abstract: In some embodiments, the present invention provides a method of purifying a protein of interest with a reduced level of aggregation formation in cation exchange (CEX) chromatography, comprising: (a) providing a mixture comprising the protein of interest and one or more contaminants; (b) loading the mixture onto a CEX resin coupled with arginine; and (c) eluting the protein of interest from the resin, thereby purifying the protein of interest with a reduced level of aggregation formation in CEX chromatography.
    Type: Grant
    Filed: August 10, 2017
    Date of Patent: March 16, 2021
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Zhengjian Li, Xuankuo Xu, Chao Huang, Zhiqiang Chen
  • Patent number: 10941205
    Abstract: Herein are provided bispecific anti-human A-beta/human transferrin receptor antibodies and methods of using the same.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: March 9, 2021
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Harald Duerr, Sebastian Fenn, Ulrich Goepfert, Sabine Imhof-Jung, Christian Klein, Laurent Lariviere, Michael Molhoj, Joerg Thomas Regula, Petra Rueger, Wolfgang Schaefer
  • Patent number: 10941382
    Abstract: The present invention provides: a platelet production promoter that contains one or more substances selected from the group consisting of Wnt inhibitors and FMS-like tyrosine kinase (FLT) inhibitors; and a platelet production method that uses this platelet production promoter.
    Type: Grant
    Filed: January 30, 2017
    Date of Patent: March 9, 2021
    Assignees: Kyoto University, Megakaryon Corporation
    Inventors: Koji Eto, Hideya Seo, Akira Ota, Yukitaka Ito, Yasuko Hazama
  • Patent number: 10942178
    Abstract: A device detects a target molecule in a sample in a sample container to measure the target molecule. A first particle is functionalized with a first binding molecule capable of specifically binding to said target molecule. A surface structure includes a second binding molecule. The surface structure covers a flat sensor or is present on a second particle. The first particle is capable of binding the second binding molecule of the surface structure directly or indirectly. The first and/or second binding molecule is indirectly attached to the particle surface of the first and/or second particle and/or the flat sensor surface via a long and rigid linker molecule. A length and a consistency of the linker molecule is selected such as to result in an average extension length of the linker of more than 60 nm. A number of particle clusters or of bound particles is directly or inversely related to an amount of the target molecules present in the sample.
    Type: Grant
    Filed: November 13, 2012
    Date of Patent: March 9, 2021
    Assignee: Koninklijke Philips N.V.
    Inventors: Toon Hendrik Evers, Maatje Koets
  • Patent number: 10934355
    Abstract: Aspects of the present disclosure include methods of treating a subject to reduce adhesion formation, the method comprising administering to a subject in need of thereof an agent that that targets adhesion-formation by injured mesothelial cells. The agent can act at a variety of checkpoints in the development of adhesions by injured mesothelial cells, including: targeting the injured mesothelial cells for destruction, recruiting inflammatory macrophages to the site of adhesion, preventing neutrophil recruitment to the site of adhesion, and/or inhibiting the expression or activity of a gene product whose expression is induced in the injured mesothelial cells. Compositions and kits for performing the methods are also provided.
    Type: Grant
    Filed: May 1, 2017
    Date of Patent: March 2, 2021
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Jonathan Tsai, Nathaniel Fernhoff, Rahul Sinha, Yuval Rinkevich, Irving L. Weissman
  • Patent number: 10919977
    Abstract: A bispecific tetravalent antibody comprising an IgG having a pair of heavy chains and a pair of light chains, and two scFv components being connected to either C or N terminals of the heavy or light chains. The bispecific tetravalent antibody may have a binding specificity for two different members of EGFR family.
    Type: Grant
    Filed: December 19, 2015
    Date of Patent: February 16, 2021
    Assignees: SYSTIMMUNE, INC., Sichuan Baili Pharmaceutical Co. Ltd.
    Inventors: Zeren Gao, Phil Tan, Brian R. Kovacevich, Blair R. Renshaw, Jeffrey B. Adamo, Nga Sze Amanda Mak, Shi Zhuo, Lan Chen, Yi Zhu
  • Patent number: 10913803
    Abstract: The present invention is directed to novel heterodimeric antibodies.
    Type: Grant
    Filed: April 4, 2018
    Date of Patent: February 9, 2021
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal, Sung-Hyung Lee
  • Patent number: 10912842
    Abstract: The invention provides murine, chimeric, and humanized antibodies that specifically bind to CD123 and conjugates thereof.
    Type: Grant
    Filed: June 9, 2016
    Date of Patent: February 9, 2021
    Assignee: Seattle Genetics, Inc.
    Inventors: May Kung Sutherland, Lori Westendorf, Django Sussman
  • Patent number: 10894821
    Abstract: The invention relates generally to activatable antibodies and methods of making and using these activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: January 19, 2021
    Assignee: CytomX Therapeutics, Inc.
    Inventors: Henry Bernard Lowman, Shouchun Liu